The primary goal of treating patients with IBD, as the Selecting Therapeutic Targets in Inflammatory Bowel Disease initiative (STRIDE-II) states [19], is to maintain long-term health-related quality of life by obtaining clinical response and remission, endoscopic healing, normalization of C-reactive protein, erythrocyte sedimentation rate and calprotectin [19]. This evidence concerns the gene CRP and inflammatory bowel disease.